Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AIM ImmunoTech Inc. (NYSE American: AIM) announced the appointment of W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB) on April 12, 2023. Dr. Burnette has extensive experience in biomedical research and has held key roles in notable organizations, contributing to the development of various vaccines. AIM’s CEO, Thomas K. Equels, expressed confidence that Dr. Burnette's leadership will enhance the company's therapeutic pipeline, particularly its lead product, Ampligen®. The SAB consists of experts from diverse fields, reflecting AIM's commitment to advancing treatments for cancers and viral diseases.
AIM ImmunoTech Inc. (NYSE American: AIM) announced the IRB approval for its Phase 2 study, AMP-518, evaluating Ampligen as a treatment for post-COVID conditions. The trial will assess the drug's efficacy in reducing fatigue among patients through various metrics, including the PROMIS® Fatigue Score. About 80 subjects aged 18 to 60 will be enrolled across 10 centers in the U.S. AIM expects to commence patient enrollment and dosing in Q2 2023. This development emphasizes the company's commitment to addressing a significant unmet medical need related to chronic fatigue-like symptoms following COVID-19.